Cancer Immunochemotherapy: Preliminary Studies with Triazene Compounds

  • Grazia Graziani
  • Stefania D’Atri
  • Anna Giuliani
  • Annibale Franchi
  • Daniela Piccioni
  • Giuseppe Papa
  • Enzo Bonmassar


One of the most challenging problems of cancer immunotherapy in the clinic concerns the poor immune response of the host for the autochthonous tumor. This is, at least in part, due to the scarce immunogenicity of neoplastic cells, which are not recognized by host’s natural or antigen-dependent immune apparatus. In order to overcome this difficulty, the immunopharmacological approach of “Chemical Xenogenization” (CX) has been introduced by our laboratory in 1970 (1). It has been found that in vivo treatment of leukemia-bearing mice with triazene compounds (TZC) leads to the appearance of novel transplantation antigens on the membrane of neoplastic cells (2–4). TZC-treated cells are rejected by syngeneic hosts and elicit specific cytotoxic T lymphocyte (CTL) responses (1–14). The principal features of CX in mouse leukemias are summarized in Table 1.


Acute Myelogenous Leukemia Transplantation Antigen Acute Myelogenous Leukemia Blast Liquid Hybridization Murine Lymphoma Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    E.Bonmassar, A.Bonmassar, S.Vadlamudi, and A.Goldin, Immunological alteration of leukemic cells in vivo after treatment with an antitumor agent,Proc.Natl.Acad.Sci. (USA) 66:1089 (1970).PubMedCrossRefGoogle Scholar
  2. 2.
    E.Bonmassar, A.Bonmassar, S.Vadlamudi, and A.Goldin, Antigenic changes of L1210 leukemia in mice treated with 5-(3–3’-dimethyl-l-triazeno)-imidazole-4-carboxamide, Cancer Res. 32: 1446 (1972).PubMedGoogle Scholar
  3. 3.
    A.Nicolin, F.Spreafico, E.Bonmassar, and A.Goldin, Antigenic changes of L5178Y lymphoma after treatment with 5-(3–3’-dimethyl-1-triazeno)-imidazole-4-carboxamide in vivo, J.Natl.Cancer Inst. 56: 89 (1976).PubMedGoogle Scholar
  4. 4.
    P.Puccetti, L.Romani, and M.C.Fioretti, Chemical xenogenization of experimental tumors,Cancer Metast. Reviews 6:93 (1987).CrossRefGoogle Scholar
  5. 5.
    M.Allegrucci, P.Fuschiotti, P.Puccetti, L.Romani, and M.C.Fioretti, Changes in the tumorigenic and metastatic properties of murine melanoma cells treated with a triazene derivative, Clin.Expl.Metastasis 7: 329 (1989).CrossRefGoogle Scholar
  6. 6.
    B.Nardelli, A.R.Contessa, L.Romani, G.Sava, C.Nisi, and M.C.Fioretti, Immunogenic changes of murine lymphoma cells following in vitro treatment with aryl-triazenederivatives,Cancer Immunol. Immunother. 16:157 (1984).Google Scholar
  7. 7.
    A.R.Contessa, A. Bonmassar, A.Giampietri, A.Circolo, A.Goldin, and M.C.Fioretti, In vitro generation of a highly immunogenic subline of L1210 leukemia following exposure to 5-(3–3’-dimethyl-l-triazeno)-imidazole-4- carboxamide, Cancer Res. 41:2476 (1981).PubMedGoogle Scholar
  8. 8.
    D.P.Houchens, E.Bonmassar, M.R.Gaston, M.Kende, and A.Goldin, Drug-mediated immunogenic changes of virus-induced leukemia in vivo, Cancer Res. 36: 1347 (1976).PubMedGoogle Scholar
  9. 9.
    O.Marelli, P.Franco, G.Canti, L.Ricci, N.Prandoni, A.Nicolin, H.Festenstein, DTIC xenogenized lines obtained from an L1210 clone: clonal analysis of cytotoxic T lymphocyte reactivity, Br.J.Cancer 58: 171 (1988).PubMedCrossRefGoogle Scholar
  10. 10.
    M.C.Fioretti, R.Bianchi, L.Romani, and E.Bonmassar, Drug-induced immunogenic changes of murine leukemic cells: dissociation of onset of resistance and emergence of novel immunogenicity, J.Nat.Cancer Inst. 71: 1247 (1983).PubMedGoogle Scholar
  11. 11.
    C.Riccardi, M.C.Fioretti, A.Giampietri, P.Puccetti, and A.Goldin, Growth and rejection patterns of murine lymphoma cells antigenically altered following drug treatment in vivo, Transplantation 25: 63 (1978).PubMedCrossRefGoogle Scholar
  12. 12.
    A.Nicolin, A.Bini, E.Coronetti, and A.Goldin, Cellular immune response to a drug treated L5178Y lymphoma subline, Nature 251: 654 (1974).PubMedCrossRefGoogle Scholar
  13. 13.
    A.Santoni, Y.Kinney, A.Goldin, Secondary cytotoxic response in vitro against Moloney lymphoma cells antigenically altered by drug-treatment in vivo, J.Natn.Cancer Inst. 60: 109 (1978).Google Scholar
  14. 14.
    L.Romani, M.C.Fioretti, and E.Bonmassar, In vitro generation of primary cytotoxic lymphocytes against L5178Y leukemia antigenically altered by 5-(3,3’dimethyl-l-triazeno)-imidazole-4-carboxamide in vivo, Transplantation 28:218 (1979).PubMedCrossRefGoogle Scholar
  15. 15.
    L.Romani, P.Puccetti, M.C.Fioretti, and M.G. Mage, Humoral response against murine lymphoma cells xenogenized by drug treatment in vivo. Int.J. Cancer 36:225 (1985).PubMedCrossRefGoogle Scholar
  16. 16.
    C.Testorelli, Y.I.Archetti, P.Aresca, and L.Del Vecchio, Monoclonal antibodies to the L1210 murine leukemia cell line and to a drug-altered subline. Cancer Res.45: 5299 (1985).PubMedGoogle Scholar
  17. 17.
    L.Romani, U.Grohmann, F.Fazioli, P.Puccetti, M.G.Mage, and M.C.Fioretti, Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens, Cancer Immunol. Immunother . 26:48 (1988).Google Scholar
  18. 18.
    A.Giampietri, M.C.Fioretti, A.Goldin, and E.Bonmassar, Drug-mediated antigenic changes in murine leukemia cells: antagonistic effects of Quinacrine, an antimutagenic compound, J.Natl. Cancer Inst. 64:297 (1980).PubMedGoogle Scholar
  19. 19.
    T.Boon, Antigenic tumor cell variants obtained with mutagens, Adv.Cancer Res. 39: 121 (1983).PubMedCrossRefGoogle Scholar
  20. 20.
    E.De Plaen, C.Lurquin, A.Van Pel, B.Mariame’, J.P.Szikora, T.Wolfel, C.Sibille, P.Chomez, and T.Boon, Immunogenic (tum) variants of mouse tumor P815: cloning of the gene of tum antigen P91A and identification of the tum mutation. Proc.Natl.Acad.Sci.(USA) 85: 2274 (1988).PubMedCrossRefGoogle Scholar
  21. 21.
    C.V.Catapano, M.Broggini, E.Erba, M.Ponti, L.Mariani, L.Citti, and M.D’Incalci, In vitro and in vivo methazolastone induced DNA damage and repair in L1210 leukemia sensitive and resistant to chloroethylnitrosoureas, Cancer Res. 47:4884 (1987).PubMedGoogle Scholar
  22. 22.
    U.Grohmann, L.Binaglia, P.Puccetti, and M.C.Fioretti, Murine leukemia virus gp70 antisense oligonucleotides inhibit CTL-mediated lysis of a drug-treated lymphoma, 8th Int. Congr. of Immunology, Budapest, Hungary August 23–28, 1992.Google Scholar
  23. 23.
    A.Giampietri, A.Bonmassar, P.Puccetti, A.Circolo, A.Goldin, and E.Bonmassar, Drug-mediated increase of tumor immunogenicity in vivo for a new approach to experimental cancer immunotherapy, Cancer Res. 41: 681 (1981).PubMedGoogle Scholar
  24. 24.
    L.Romani, M.C.Fioretti, R.Bianchi, B.Nardelli, and E.Bonmassar, Intracerebral adoptive immunotherapy of a murine lymphoma antigenically altered by drug treatment in vivo, JNCI 68: 817 (1982).PubMedGoogle Scholar
  25. 25.
    A.E.Pegg, L.Wiest, R.S.Foote, S.Mitra, and W.Perry, Purification and properties of 06-methylguanine-DNAtransmethylase from rat liver, J.Biol.Chem. 258: 2327 (1983)Google Scholar
  26. 26.
    J.Domoradzki, A.E.Pegg, M.E.Dolan, V.M.Maher, and J.J.McCormick, Correlation between 06-methylguanine-DNAmethyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N’nitro-N-nitrosoguanidine, Carcinogenesis 5: 1641 (1984).PubMedCrossRefGoogle Scholar
  27. 27.
    A.Franchi, G.Papa, S.D’Atri, D.Piccioni, M.Masi, E.Bonmassar, Cytotoxic effects of Dacarbazine in patients with acute myelogenous leukemia: a pilot study, Haematologica 77: 146 (1992).PubMedGoogle Scholar
  28. 28.
    M.C.Fioretti, L.Romani, E.Bonmassar, Antigenic changes related to drug-action, in: “Biology of Cancer” (13th Int. Cancer Congress, Part B), E.A.Mirand, W.B.Hutchinson, and E.Mihich eds., Alan R.Liss Inc., New York (1983).Google Scholar
  29. 29.
    G.P.Margison, D.P.Cooper, J.Brennan, Cloning of the E.Coli 06 methylguanine and methylphosphotriester methyl transferase gene using a functional DNA repair assay, Nucleic Acid Res. 13: 1939 (1985).PubMedCrossRefGoogle Scholar
  30. 30.
    G.N.Major, E.F.Gardner, A.F.Carne, P.D.Lawley, Purification to homogeneity and partial amino acid sequence of a fragment which includes the methyl acceptor site of the human DNA repair protein for 06methylguanine, Nucleid Acid Res. 18: 1351 (1990).CrossRefGoogle Scholar
  31. 31.
    K.Welte, E.Platzer, L.Lu et al, Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor,Proc. Natl. Acad. Sci. (USA) 82:1526 (1985).CrossRefGoogle Scholar
  32. 32.
    G.Graziani, D.Pasqualetti, M.Lopez, C.D’Onofrio, A.M.Testi, F.Mandelli, R.C.Gallo and E.Bonmassar, Increased susceptibility of peripheral mononuclear cells of leukemic patients to HTLV-I infection in vitro. Blood 69: 1175 (1987).PubMedGoogle Scholar
  33. 33.
    G.D.Ehrlich, S.Greenberg and M.Abbot, Detection of human T-cell lymphoma/leukemia viruses, in: “PCR protocol. A guide to methods and applications”, M.A.Innis, D.H.Gelfand, J.J. Sninsky, and T.J.White eds., Academic Press Inc. (1990).Google Scholar
  34. 34.
    M.A.Abbot, B.J.Poiesz, B.C.Byrne, S.Kwok, J,J.Sninsky and G.D.Ehrlich, Enzimatic gene amplification: qualitative and quantitative methods for detecting proviral DNA amplification in vitro, J.Infect.Dis. 158: 1158 (1988).CrossRefGoogle Scholar
  35. 35.
    S.Knok, G.Ehrlich, B.Poiesz. R. Kalish and J.J.Sninsky, Enzymatic amplification of HTLV-I viral sequences from peripheral blood mononuclear cells and infected tissues, Blood 72: 1117 (1988).Google Scholar
  36. 36.
    P.Robins, A.L.Harris, L.Goldsmith, and T.Lindahl, Cross-linking of DNA, produced by chloroethylnitrosourea is prevented by 06-methylguanine-DNA-methyltransferase, Nucleic Acid Res. 11: 7743 (1983).PubMedCrossRefGoogle Scholar
  37. 37.
    T.J.Panella, D.C.Smith, S.C.Schold, M.P.Rogers, E.P.Winer, R.L.Fine, J.Crawford, J.E.Herndon II, and D.L.Trump, Modulation of 06-alkylguanine-DNA- alkyltransferase-mediated Carnmustine resistance using Streptozotocin: a phase I trial, Cancer Res. 52: 2456 (1992).PubMedGoogle Scholar
  38. 38.
    B.Nardelli, P.Puccetti, L.Romani, G.Sava, E.Bonmassar, and M.C.Fioretti, Chemical xenogenization of murine lymphoma cells with triazene derivatives: immunotoxicological studies, Cancer Immunol.Immunother . 17:213 (1984).PubMedCrossRefGoogle Scholar
  39. 39.
    S.D’Atri, L.Tentori, M.Tricarico, and E.Bonmassar, Effects of triazenes on immune responses, in: “Triazenes. Chemical, Biological and Clinical aspects”, T.Giraldi, T.A.Connors, and G.Cartei eds., Plenum Press, New York-London (1990).Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Grazia Graziani
    • 2
  • Stefania D’Atri
    • 1
  • Anna Giuliani
    • 1
  • Annibale Franchi
    • 2
  • Daniela Piccioni
    • 2
  • Giuseppe Papa
    • 3
  • Enzo Bonmassar
    • 1
  1. 1.Institute of Experimental MedicineNational Council of Research (CNR)RomeItaly
  2. 2.Department of Experimental Medicine and Biochemical SciencesUniversity of Rome Tor VergataRomeItaly
  3. 3.Department of Internal MedicineS. Eugenio HospitalRomeItaly

Personalised recommendations